- Home
- JGH vs ENTA Comparison
JGH vs ENTA Comparison
Compare JGH & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- ENTA
- Stock Information
- Founded
- JGH 2014
- ENTA 1995
- Country
- JGH United States
- ENTA United States
- Employees
- JGH N/A
- ENTA N/A
- Industry
- JGH Investment Managers
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- JGH Finance
- ENTA Health Care
- Exchange
- JGH Nasdaq
- ENTA Nasdaq
- Market Cap
- JGH 304.1M
- ENTA 245.4M
- IPO Year
- JGH N/A
- ENTA 2013
- Fundamental
- Price
- JGH $13.05
- ENTA $9.53
- Analyst Decision
- JGH
- ENTA Buy
- Analyst Count
- JGH 0
- ENTA 4
- Target Price
- JGH N/A
- ENTA $20.00
- AVG Volume (30 Days)
- JGH 73.9K
- ENTA 115.7K
- Earning Date
- JGH 01-01-0001
- ENTA 11-25-2024
- Dividend Yield
- JGH 9.85%
- ENTA N/A
- EPS Growth
- JGH N/A
- ENTA N/A
- EPS
- JGH N/A
- ENTA N/A
- Revenue
- JGH N/A
- ENTA $71,960,000.00
- Revenue This Year
- JGH N/A
- ENTA N/A
- Revenue Next Year
- JGH N/A
- ENTA $5.14
- P/E Ratio
- JGH N/A
- ENTA N/A
- Revenue Growth
- JGH N/A
- ENTA N/A
- 52 Week Low
- JGH $10.36
- ENTA $8.51
- 52 Week High
- JGH $12.85
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- JGH 51.34
- ENTA 26.79
- Support Level
- JGH $13.08
- ENTA $10.84
- Resistance Level
- JGH $13.33
- ENTA $10.89
- Average True Range (ATR)
- JGH 0.11
- ENTA 0.52
- MACD
- JGH 0.03
- ENTA -0.19
- Stochastic Oscillator
- JGH 51.72
- ENTA 0.35
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.